Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis

Digestive Diseases and Sciences

Volumn 59, Issue 4, 2014, Pages 829-837

  Yoon, Jin Young ^a   Park, Soo Jung ^a   Hong, Sung Pil ^a   Kim, Tae Il ^a   Kim, Won Ho ^a   Cheon, Jae Hee ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

C reactive protein; Disease activity index; Endoscopic activity index; Erythrocyte sedimentation rate; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; MESALAZINE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; COLONOSCOPY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; ENDOSCOPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HANAUER SIGMOIDOSCOPIC INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MAYO ENDOSCOPIC SCORE; MIDDLE AGED; MODIFIED BARON SCORE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACHMILEWITZ ENDOSCOPIC ACTIVITY INDEX; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; ULCERATIVE COLITIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; COLONOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SIGMOIDOSCOPY; YOUNG ADULT;

EID: 84897032025     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2907-3     Document Type: Article

References (33)

1. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1-23. (Pubitemid 351179487)
2. Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851-1858.
3. Park JJ, Cheon JH, Kim BY, et al. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Dig Dis Sci. 2009;54:1525-1531.
4. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel disease: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-169.
5. Sandborn W, Feagan B, Radford-Smith G, et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomized double blind, placebo controlled trial. Gut. 2004;53:1485-1493. (Pubitemid 39265271)
6. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic or unnecessary toys? Gut. 2006;55:426-431. (Pubitemid 43268284)
7. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57:1518-1523.
8. Naber AHJ, De Jong DJ. Assessment of disease activity in inflammatory bowel disease: relevance for clinical trials. Neth J Med. 2003;61:105-110. (Pubitemid 39089380)
9. Kiss LS, Szamosi T, Molnar T, et al. Early clinical remission and normalization of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2001;34:911-922.
10. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422. (Pubitemid 47187355)
11. Cheon JH, Kim WH. Recent advances of endoscopy in inflammatory bowel diseases. Gut Liver. 2007;1:118-125.
12. Nikolaus S, Schreiber S. Review article: diagnostics of inflammatory bowel disease. Gastroenterology . 2007;133:1670-1689. (Pubitemid 350029755)
13. Shelat SG, Chacosky D, Shibutani S. Differences in erythrocyte sedimentation rates using the Westergren method and a centrifugation method. Am J Clin Pathol. 2008;130:127-130.
14. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999; 45:2136-2141.
15. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786.
16. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13:833-837. (Pubitemid 9067125)
17. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629. (Pubitemid 18010466)
18. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476. (Pubitemid 41770166)
19. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. BMJ. 1964;1:89-92.
20. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the a 4b7 integrin. N Engl J Med. 2005;352:2499-2507. (Pubitemid 41007865)
21. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86. (Pubitemid 19032930)
22. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993;88:1188-1197. (Pubitemid 23219711)
23. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ. 1955;2:1041-1048.
24. Tall AR. C-reactive protein reassessed. N Engl J Med. 2004;350:1450-1452. (Pubitemid 38420000)
25. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454. (Pubitemid 29084777)
26. Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, radiographic, and endoscopic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712. (Pubitemid 41271173)
27. Gross V, Andus T, Caesar I, et al. Evidence for continues stimulation of interleukin-6 production in Crohn's disease. Gastroenterology. 1992;109:514-519.
28. Osada T, Ohkusa T, Okayasu I, et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol. 2008;23:S262-S267.
29. Lok KH, Ng CH, Hung HG, et al. Correlation of serum biomarkers with clinical severity and mucosal inflammation in Chinese ulcerative colitis patients. J Dig Dis. 2008;9:219-224.
30. Sachar DB, Smith H, Chan S, et al. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol. 1986;8:647-650. (Pubitemid 17207510)
31. Gomes P, du Boulay CD, Smith CL, et al. Relationship between disease indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986;27:92-95. (Pubitemid 16134482)
32. Ha JS, Lee JS, Kim HJ, et al. Comparative usefulness of erythrocyte sedimentation rate and C-reactive protein in assessing the severity of ulcerative colitis. Korean J Gastroenterol. 2006;48:313-320.
33. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535-542.